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TO THE EDITOR
Cutaneous T-cell lymphomas (CTCL) are
a heterogenous group of non-Hodgkin’s
lymphomas of skin-trafficking T lympho-
cytes (Diamandidou et al., 1996). CTCL
patients often suffer from intense pruritus,
which can cause significant morbidity
and decreased quality of life (Sampogna
et al., 2009; Ahern et al., 2012). At
present, the underlying pathophysiologic
mechanisms of itch in CTCL are not fully
known, and therefore there is a
significant unmet need for clinically
effective treatments in reducing CTCL-
associated itch (Ahern et al., 2012).
IL-31, a short-chain 4-helix-bundle
cytokine produced primarily by skin-
homing CD4 T cells, was found to
cause dermatitis, alopecia, and pruritus
when overexpressed in transgenic mice
(Dillon et al., 2004). Moreover, IL-31
mRNA and protein levels are increased
in pruritic human skin diseases includ-
ing atopic dermatitis, allergic contact
dermatitis, and prurigo nodularis, and
serum IL-31 levels correlate with the
severity of pruritus in atopic der-
matitis (Sonkoly et al., 2006; Raap
et al., 2008).
Recently, increased IL-31 protein was
also reported in the serum of patients
with CTCL, and, although its levels
correlated with advanced CTCL disease
stage, no data were presented correlat-
ing levels with pruritus severity
(Miyagaki et al., 2012; Ohmatsu et al.,
2012). Given the association of IL-31
with pruritic skin diseases and its recent
discovery in CTCL, we investigated
IL-31 in CTCL patients with mycosis
fungoides or Se´zary syndrome.
By using quantitative reverse trans-
criptase in real time, we tested the cells
of 29 CTCL patients with leukemic
involvement and 13 healthy, aged-
matched controls for levels of IL-31
mRNA. The mean value of IL-31 mRNA
from 29 patients was 24.73 with a
median of 2.61 (interquartile range
(IQR) 1.21, 10.56) when normalized
to the mean value of 13 normal,
aged-matched controls, assigned a
value of 1.0.
We retrospectively reviewed physi-
cian notes to assess whether each
patient complained of itch at that time
of sample collection, and if present
whether that itch had increased,
decreased, or remained the same com-
pared with the previous visit. On the
basis of this retrospective chart review,
IL-31 mRNA levels significantly corre-
lated with patients experiencing marked
pruritus at the time of sample collection
(marked pruritus, mean 50.02, median
9.99 (IQR 5.86, 20.76); decreasing/
absent pruritus, mean 3.94, median
1.83 (IQR 0.64, 3.25); Wilcoxon rank
sum P¼0.006) (Figure 1a).
We next tested the serum of 40 CTCL
patients for the presence of IL-31 protein,
26 with pruritus at the time of sample
collection and 14 without pruritus, and
observed a statistically significant differ-
ence in IL-31 levels between pruritic
and non-pruritic patients (pruritic, mean
IL-31 value 88.32 pg ml 1, median 9.71
(IQR 7.80, 29.62); non-pruritic, mean
11.47 pg ml1, median 7.80 (IQR 7.80,
7.80); Wilcoxon rank sum P¼ 0.008;
Figure 1b). There were no significant
differences in age or gender between
the marked pruritic and decreasing/
absent pruritus patients, and there was
also no correlation between IL-31
mRNA or protein and patient stage, as
the majority of patients tested in our
sampling were advanced stages 3A, 3B,
or 4A (Supplementary Table S1 online).
The malignant cells in CTCL are
typically CD3þ CD4þ CD26
T lymphocytes that may also express a
single dominant Vb TCR (Bernengo
et al., 2001; Jones et al., 2001;
Yawalkar et al., 2003). Using flow
cytometry, we tested 15 CTCL patients
(two stage 3A, four stage 3B, nine stage
4A) and seven age-matched, healthy
volunteers for intracellular IL-31
expression. We found that eight
patients, all of whom were pruritic,
expressed intracellular IL-31 by their
stimulated CD4 T cells (Figure 2a).
Among these eight patients, seven
patients predominately expressed IL-31
within their CD3þ CD4þ CD26
T lymphocytes in distinction to their
CD3þ CD4þ CD26þ lymphocytes
(CD4þ CD26 : mean 3.22%, median
2.07 (IQR 0.72, 5.69); CD4þ CD26þ :
mean 0.744%, median 0.55 (IQR 0.11,
1.15), P¼ 0.0357, Wilcoxon matched-
pairs sign-ranked test, Supplementary
Figure S1 online). We detected only
minimal expression of IL-31 in two
non-pruritic patients (representative
patient, Figure 2b) and in healthy volun-
teer cells (o0.35%, data not shown).
In addition, three of eight IL-31-posi-
tive patients had a detectable single,
dominant TCR Vb clone, as determined
by a panel of commercially available Vb
antibodies. We stained the cells of these
patients with their specific anti-Vb anti-
body and report that in all three cases
CD4þ Vb-positive cells, in comparison
with CD4þ Vb-negative cells, were
the predominant producers of IL-31
(representative patient, Figure 2c).
We also investigated whether
clinical resolution of pruritus correlates
with declining IL-31 protein. Patient 1Accepted article preview online 22 May 2013; published online 27 June 2013
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Figure 1. Peripheral blood mononuclear cell (PBMC) IL-31 mRNA and serum IL-31 correlates with marked pruritic symptoms in cutaneous T-cell
lymphoma (CTCL) patients. (a) PBMCs were stimulated with phorbol 12-myristate 13-acetate (PMA)/ionomycin. IL-31 mRNA isolated from PBMCs of CTCL
patients with decreasing or absent pruritus versus those with marked pruritus, P¼ 0.006. Note that all CTCL patient mRNA values were standardized relative to the
average values from a selected pool of 13 aged-matched, normal controls. Error bars: mean±SEM (n: decreasing/absent pruritus¼16; marked pruritus¼ 13).
(b) Serum IL-31 levels in CTCL patients without pruritus (n¼ 14) versus those with pruritus (n¼ 24), P¼0.0083. Error bars: mean±SEM (n: no pruritus¼ 14;
pruritus¼26). Note that the linear range of the assay was 7.8 pg ml1 and that all samples with a value below 7.8 pg ml1 or those without any detectable IL-31
were assigned a value of 7.8 pg ml1 and are colored in red.
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Figure 2. IL-31 is produced by malignant CD4þ CD26 /CD4þ Vbþ CTCL cells. Fifteen cutaneous T-cell lymphoma (CTCL) patients’ CD4 T cells, stimulated
with phorbol 12-myristate 13-acetate (PMA)/ionomycin, were assessed for intracellular expression of IL-31 by flow cytometry. (a) Representative plots of IL-31
expression from cells without (left) and with (right) PMA/ionomycin stimulation. (b) Representative flow cytometric plot of IL-31 expression from a non-pruritic
patient. (c) Representative plot of IL-31 expression from CD4þ Vbþ CTCL cells.
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initially presented with diffuse intract-
able pruritus, 17.4 pg ml1 serum IL-31,
and 6.32% IL-31-positive CD4þ
CD26 cells. After multimodality ther-
apy with photopheresis, IFN-a, and oral
bexarotene, the patient had near resolu-
tion of pruritus, undetectable serum
IL-31, and only 1.1% IL-31-positive
CD4þ CD26 cells (Supplementary
Figure S2 online, top). Patient 3 pre-
sented with diffuse intractable pruritus,
a dominant detectable Vb clone
(483% of CD4 T-cells were Vbþ ),
and 2.83% of CD4þ Vbþ cells posi-
tive for IL-31. After similar multimodal-
ity treatment, the patient had resolution
of pruritus, decreased Vbþ cells
(28.6% of CD4 cells Vbþ ), and
undetectable CD4þ Vbþ IL-31þ
cells (o0.10%) (Supplementary Figure
S2 online, bottom).
In this report, we confirm that PBMC-
derived IL-31 mRNA is increased in
CTCL and that it significantly correlates
with patients experiencing marked prur-
itus at the time of sample collection.
Furthermore, 14 of 26 pruritic patients
(53%) had detectable serum IL-31,
whereas serum IL-31 protein was not
detectable in 13 of 14 non-pruritic CTCL
patients (92%). It should be noted that
our ELISA was less sensitive than that
used by Ohmatsu et al., and we may
have not identified some patients who
produce less than 7.8 pg ml 1 of IL-31,
the lower limit of our assay. In addition,
it should be noted that we classified
patients based on their stage at the time
of diagnosis, and that some advanced-
stage patients were probably non-pruri-
tic when tested, given that they had
already initiated multimodality therapy.
Importantly, our flow cytometry results
showing that in some patients only a
small percentage of lymphocytes pro-
duce IL-31 are consistent with the report
by Szegedi et al. (2012) in which, using
the same IL-31 polyclonal antibody,
only 1% of CD4 T cells were found to
produce IL-31.
It is not yet fully clear as to what drives
the production of IL-31. Although Se´zary
syndrome patients are frequently colo-
nized by Staphylococcus aureus, which
has been shown to increase IL-31 expres-
sion, this is probably not the primary
mechanism of IL-31 production given that
there were S. aureus–colonized Se´zary
syndrome patients included in this study
who did not produce IL-31 (Sonkoly et al.,
2006; Talpur et al., 2008).
In summary, in this study, we report
that CD4þCD26- malignant cells speci-
fically produce IL-31 and that clinical
resolution of pruritus correlates with
decreased IL-31 levels in the circulation.
Given this strong association, IL-31 should
be considered as a potential therapeutic
target for anti-itch treatment in CTCL.
Studies were conducted in accor-
dance with the Declaration of Helsinki
and approved by the University of
Pennsylvania’s Institutional Review
Board (IRB). All subjects provided writ-
ten informed consent.
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